Doxorubicin resistance in a novel in vitro model of human pleomorphic liposarcoma associated with alternative lengthening of telomeres

Molecular Cancer Therapeutics

Volumn 9, Issue 3, 2010, Pages 682-692

  Mitchell, Marcy A ^a   Johnson, Jay E ^b   Pascarelli, Kara ^a   Beeharry, Neil ^c   Chiourea, Maria ^d   Gagos, Sarantis ^d   Lev, Dina ^e   Von Mehren, Margaret ^c   Kipling, David ^f   Broccoli, Dominique ^a  

^a MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^e UNIVERSITY OF TEXAS   (United States)

^f CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; DOXORUBICIN; IFOSFAMIDE; TRANSCRIPTOME;

ADULT; ARTICLE; CANCER CELL CULTURE; CELL STRAIN LS2; CONTROLLED STUDY; DNA DAMAGE; GENOME; GENOMICS; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSARCOMA; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; SOFT TISSUE SARCOMA; TELOMERE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; HELA CELLS; HUMANS; LIPOSARCOMA; MODELS, THEORETICAL; SOFT TISSUE NEOPLASMS; TELOMERE;

EID: 77949662980     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0705     Document Type: Article

References (37)

1. Matushansky I, Hernando E, Socci ND, et al. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol 2008;172:1069-80.
2. Singer S, Socci ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007;67:6626-36.
3. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279:349-52.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
5. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
6. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 2006;12:1133-8.
7. Cesare AJ, Reddel RR. Telomere uncapping and alternative lengthening of telomeres. Mech Ageing Dev 2008;129:99-108.
8. Johnson JE, Varkonyi RJ, Schwalm J, et al. Multiple mechanisms of telomere maintenance exist in liposarcomas. Clin Cancer Res 2005; 11:5347-55.
9. Costa A, Daidone MG, Daprai L, et al. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 2006;66:8918-24.
10. Jeyapalan JN, Mendez-Bermudez A, Zaffaroni N, Dubrova YE, Royle NJ. Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT-associated PML bodies. Int J Cancer 2008;122:2414-21.
11. Johnson JE, Gettings EJ, Schwalm J, et al. Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms. Cancer Res 2007;67:9221-8.
12. Wabitsch M, Bruderlein S, Melzner I, et al. LiSa-2, a novel human liposarcoma cell line with a high capacity for terminal adipose differentiation. Int J Cancer 2000;88:889-94.
13. Mancini A, Borrelli A, Masucci MT, et al. A conditioned medium from a human liposarcoma-derived cell line induces p53-dependent apoptosis in several tumor cell lines. Oncol Rep 2000;7:629-37.
14. Nishio J, Iwasaki H, Ishiguro M, et al. Establishment of a novel human dedifferentiated liposarcoma cell line, FU-DDLS-1: conventional and molecular cytogenetic characterization. Int J Oncol 2003;22: 535-42.
15. Kiguchi K, Ishiwata I, Ishiwata E, et al. Establishment and characterization of a human liposarcoma cell line (HTLS) from the retroperitoneal liposarcoma. Hum Cell 2005;18:45-52.
16. Hugo ER, Brandebourg TD, Comstock CE, et al. LS14: a novel human adipocyte cell line that produces prolactin. Endocrinology 2006; 147:306-13.
17. Persson F, Olofsson A, Sjogren H, et al. Characterization of the 12q amplicons by high-resolution, oligonucleotide array CGH and expression analyses of a novel liposarcoma cell line. Cancer Lett 2008;260:37-47.
18. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
19. Broccoli D, Godley LA, Donehower LA, Varmus HE, de Lange T. Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation. Mol Cell Biol 1996;16:3765-72.
20. Grobelny JV, Godwin AK, Broccoli D. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. J Cell Sci 2000;113 Pt 24:4577-85.
21. Irizarry RA, Bolstad BM, Collin F, et al. Summaries of Affymetrix Gene-Chip probe level data. Nucleic Acids Res 2003;31:e15.
22. von Mehren M, Schilder RJ, Cheng JD, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol 2008;19:1802-9.
23. Gagos S, Chiourea M, Christodoulidou A, et al. Pericentromeric instability and spontaneous emergence of human neoacrocentric and minute chromosomes in the alternative pathway of telomere lengthening. Cancer Res 2008;68:8146-55.
24. Shaffer LG, Tommerup N. ISCN 2005: an International System for Human Cytogenetic Nomenclature. Basel (Switzerland): S. Karger; 2005.
25. Mertens F, Fletcher CD, Dal Cin P, et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes andMorPhology. Genes Chromosomes Cancer 1998;22:16-25.
26. Sreekantaiah C, Karakousis CP, Leong SP, Sandberg AA. Cytogenetic findings in liposarcoma correlate with histopathologic subtypes. Cancer 1992;69:2484-95.
27. Francis P, Namlos HM, Muller C, et al. Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 2007;8:73.
28. Burgess DJ, Doles J, Zender L, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 2008;105:9053-8.
29. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995;14:4240-8.
30. Gryaznov SM, Jackson S, Dikmen G, et al. Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent. Nucleosides Nucleotides Nucleic Acids 2007;26:1577-9.
31. Vonderheide RH. Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines 2008;7:881-7.
32. Ulaner GA, Huang HY, Otero J, et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 2003;63:1759-63.
33. Hakin-Smith V, Jellinek DA, Levy D, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003;361:836-8.
34. Henson JD, Hannay JA, McCarthy SW, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005;11:217-5.
35. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology 2006;48:13-21.
36. Orndal C, Rydholm A, Willen H, Mitelman F, Mandahl N. Cytogenetic intratumor heterogeneity in soft tissue tumors. Cancer Genet Cytogenet 1994;78:127-37.
37. LaPensee EW, Reddy SP, Hugo ER, Schwemberger SJ, Ben-Jonathan N. LS14 cells: a model for chemoresistance in liposarcoma. Cancer Biol Ther 2007;6:519-24.